← The SEC Ephemeris: the whole map
Mapi Pharma Ltd. glatiramer acetate epi
In the graph: all 1 documents (7 pages).
- Application
- NDA 218223
- Ticker
- Mapi Pharma Ltd.
- Product
- glatiramer acetate epi
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- March 8, 2024
From FDA letters and SEC filings. Not investment or medical advice.